Raubling, Germany-based Axplora, which focuses on small-molecule API manufacturing reports that its total investments initiated across its global network in 2025 will exceed €100 million ($115.6 million).
The total includes the increased amount of €60 million allocated to the ongoing expansion of its Mourenx, France site, alongside €35 million at Gropello, Italy, and €8.5 million at Vizag, India (see below). In addition, March this year saw the expansion of Axplora’s ADC (antibody-drug conjugate) manufacturing capabilities at is site in Le Mans, France.
These projects extend across several years, embedding long-term capability across the business, according to Martin Meeson, CEO. The scale of the Mourenx initiative, in particular, is giving Axplora’s teams the opportunity to expand expertise through close collaboration with a customer on a project of significant size and complexity, he adds, noting that insights and best practices developed there are now being shared across Axplora’s nine global sites.
While new modalities such as GLP-1 peptides and ADCs stand out as high-growth opportunities, small molecules remain the foundation of global pharmaceutical manufacturing, accounting for the majority of prescriptions today and well into the future, points out Meeson.
“Each euro invested is directed towards strengthening our capabilities, expanding our global network, and ensuring we are prepared to deliver the next generation of medicines with speed and reliability,” he says.
“These investments reflect the trust our customers place in us and our commitment to working side by side with them,” states Arul Ramadurai, CCO. “We dare to imagine a future where no patient waits for the medicines they need. That vision drives us to understand our customers’ needs better than anyone else, and to build the scale, expertise, and capabilities that will help bring their breakthroughs to life faster and more efficiently.”
The post Axplora Initiates Global Investments Exceeding €100m in 2025 appeared first on GEN – Genetic Engineering and Biotechnology News.
